secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001746473-25-000097
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway
--------------------------------------------------------------------------------

- Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.
- Announced ~45% workforce reduction on May 1, 2025, expected to be substantially completed by Q2 2025.
- Cash, cash equivalents and short-term investments totaled $307.1M as of March 31, 2025.
- BEACON-IPF topline data expected in Q2 2025; close-out activities ongoing.
- Interim Phase 1 data for PLN-101095 plus pembrolizumab showed three confirmed partial responses in six patients at highest dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/0001746473-25-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/plrx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001746473-25-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer